Nicotinamide Inhibits Vasculogenic Mimicry, an Alternative Vascularization Pathway Observed in Highly Aggressive Melanoma

Orit Itzhaki¹ ³, Eyal Greenberg¹-²*¹, Bruria Shalmon⁴, Adva Kubi¹, Avraham J. Treves³, Ronnie Shapira-Frommer¹, Camilla Avivi⁴, Rona Ortenberg¹-², Eytan Ben-Ami¹, Jacob Schachter¹, Michal J. Besser¹-²*, Gal Markel¹-²,⁵

¹ Ella Institute of Melanoma, Sheba Medical Center, Ramat-Gan, Israel, ² Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ³ Cancer Research Center, Sheba Medical Center, Ramat-Gan, Israel, ⁴ Department of Pathology, Sheba Medical Center, Ramat-Gan, Israel, ⁵ Talpiot Medical Leadership Program, Sheba Medical Center, Ramat-Gan, Israel

Abstract

Vasculogenic mimicry (VM) describes functional vascular channels composed only of tumor cells and its presence predicts poor prognosis in melanoma patients. Inhibition of this alternative vascularization pathway might be of clinical importance, especially as several anti-angiogenic therapies targeting endothelial cells are largely ineffective in melanoma. We show the presence of VM structures histologically in a series of human melanoma lesions and demonstrate that cell cultures derived from these lesions form tubes in 3D cultures ex vivo. We tested the ability of nicotinamide, the amide form of vitamin B3 (niacin), which acts as an epigenetic gene regulator through unique cellular pathways, to modify VM. Nicotinamide effectively inhibited the formation of VM structures and destroyed already formed ones, in a dose-dependent manner. Remarkably, VM formation capacity remained suppressed even one month after the complete withdrawal of Nicotinamide. The inhibitory effect of nicotinamide on VM formation could be at least partially explained by a nicotinamide-driven downregulation of vascular endothelial cadherin (VE-Cadherin), which is known to have a central role in VM. Further major changes in the expression profile of hundreds of genes, most of them clustered in biologically-relevant clusters, were observed. In addition, nicotinamide significantly inhibited melanoma cell proliferation, but had an opposite effect on their invasion capacity. Cell cycle analysis indicated moderate changes in apoptotic indices. Therefore, nicotinamide could be further used to unravel new biological mechanisms that drive VM and tumor progression. Targeting VM, especially in combination with anti-angiogenic strategies, is expected to be synergistic and might yield substantial anti neoplastic effects in a variety of malignancies.

Citation: Itzhaki O, Greenberg E, Shalmon B, Kubi A, Treves AJ, et al. (2013) Nicotinamide Inhibits Vasculogenic Mimicry, an Alternative Vascularization Pathway Observed in Highly Aggressive Melanoma. PLoS ONE 8(2): e57160. doi:10.1371/journal.pone.0057160

Editor: Ramon Andrade de Mello, University of Porto, Portugal

Received: September 24, 2012; Accepted: January 17, 2013; Published: February 25, 2013

Copyright: © 2013 Itzhaki et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by a grant from the Recanty foundation for medical research (GM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: markel@post.tau.ac.il (GM); michal.besser@sheba.health.gov.il (MJB)

† These authors contributed equally to this work.

Introduction

Melanoma, an aggressive malignancy arising from neural crest melanocytes, is the most lethal form of skin cancer worldwide. Melanoma is considered as the most fatal malignancy of young adults and its incidence has increased dramatically over the last 50 years [1,2]. Despite significant breakthroughs in understanding the pathobiology of melanoma, which resulted in new therapies [3,4], disseminated melanoma is still a considerable clinical problem due to the complexity of targeting the elusive metastatic phenotype [5].

The plastic notion of melanoma is characterized by the concurrent expression of genes from a variety of different cell types, including stem cells, concomitantly with reduced melanoma associate gene expression [6,7]. In particular, highly aggressive melanoma cells, in contrast to poorly aggressive ones, display substantial plasticity, exemplified by the formation of tube-like structures termed “Vasculogenic Mimicry” (VM) [8]. These structures are comprised exclusively of tumor cells but not of endothelial cells, and conduct blood cells and fluids.

VM describes the ability of tumor cells to express endothelium-and epithelium-associated genes and to form extracellular matrix (ECM)–rich tubular networks in three-dimensional cultures [8] that “mimic” the pattern of embryonic vasculogenic networks independently of angiogenesis [9,10]. Histologically, VM emerges as multiple, laminin-rich networks surrounding clusters of tumor cells, which can be stained with periodic acid-Schiff (PAS) [11]. The formation of VM channels is not an angiogenic event as it does not arise from pre-existing vessels, and despite the fact that VM channels develop de novo – a feature shared with vasculogenesis – they are clearly not blood vessels [12]. VM or a PAS-positive pattern are also associated with tumor aggressiveness, poor clinical outcome, and high risk of recurrence in patients with melanoma [8,13,14] and other malignances [15,16,17,18,19].
The fact that VM is an angiogenesis-independent mechanism, could explain why anti-angiogenic therapies have clinically failed in melanoma (reviewed in [20]), despite being macroscopically a highly “vascular” tumor. Indeed, traditional anti-angiogenic drugs, such as endostatin, have been ineffective at inhibiting VM [21,22]. Since VM is an alternative pathway for tumors to guarantee their blood supply, it is necessary to find potential therapeutic approaches that could target this alternative vascular pathway.

VE-cadherin, ephrins, focal adhesion kinase, phosphatidylinositol-3-kinase, Galectin-3, and Nodal [reviewed in [23,24] and [25]], have been identified as molecules playing a central role in VM formation and signaling. Currently, anti VM therapies are proposed by several groups. Most of them aim to either remodel the ECM and tumor microenvironment, to block biochemical and molecular signaling pathways of VM [Reviewed in [26]] or to inhibit tumor cell plasticity. Targeting Nodal, an embryonic morphogen that contributes to metastatic melanoma cell plasticity and tumorigenesis, addresses this approach [27]. Nevertheless, VM formation could qualify as a trans-differentiation process of a subpopulation of melanoma cell with epigenetic regulation [28].

Nicotinamide (NA) is the amide form of vitamin B3 (niacin), which is a component of the coenzymes nicotinamide adenine dinucleotide (NAD) and its phosphate form, NADP. NA directly impacts normal physiology due to its role in the cellular energy metabolism. NA also influences oxidative stress and modulates multiple pathways related to both cellular survival and death [29]. Additionally, this agent has an anti-inflammatory Th1 to Th2 switching effect [30] and the ability to block pro-inflammatory signal transduction pathways and mediators in vitro [29].

NA acts as an epigenetic gene regulator through unique cellular pathways via direct inhibition of four classes of enzymes, including the histone deacetylases (sirtuin) main member SIRT1 [29,31]. In cancer increased SIRT1 expression and function is followed, among other effects, by a decrease in the p53 active form which leads to genomic instability and resistance to apoptosis [32]. Particular in skin cancer, NA was shown to protect against UV-induced immunosuppression in animal models as well as in humans [33,34] and significantly reduced the incidence of UV-induced skin tumor in mice [33].

Current research suggests that NA, or vitamin B3, may play a key role in cancer prevention via its activation in cellular repair [35]. NA was extensively studied over the years for its radio-sensitizing properties [36,37], and a recent report indicated an increased efficacy of radiotherapy in locally advanced bladder carcinoma by NA [38]. In conclusion, NA has broad activities on many cell types, including regulation of cell adhesion, polarity, migration, proliferation and differentiation, and most importantly, has a de-differentiating function on differentiated cells [29,39]. Thus, we hypothesized that NA could qualify as a suitable agent for VM inhibition.

Here we demonstrate the existence of the VM phenomenon in cutaneous melanoma sections and their parallel low-passage primary melanoma cultures established in our laboratory. We further show the ability of NA to abrogate VM formation at the molecular and functional levels, as well as to alter other features of melanoma cells such as proliferation and invasion.

Results

Morphological Characteristics and Quantification of VM

Histologically, VM appears as multiple, laminin-rich PAS positive networks and surround clusters of tumor cells [11]. In order to verify the identification of VM structures in situ, we combined CD31 staining, to identify endothelial cells, and PAS staining, to determine the basement membranes of micro-vessels. Any structure containing CD31-positive immunoreactivity was defined as a blood vessel, while VM structures were strictly defined as CD31-negative PAS-positive structures (Figure 1, A-C). CD31-PAS double staining was performed on 15 tissue samples derived from melanoma patients (Table 1 and Table S1). The potential pathophysiologic relevance of VM channels was evaluated by comparing their abundance to that of CD31-positive blood vessel in each of the melanoma specimens. Notably, VM structures were detected in 14 of the 15 melanoma specimens (Figure 1D) and comprised a remarkable proportion of 40% of the total number of blood vessels, on average. These observations emphasize the potential importance of vasculogenic mimicry for melanoma development. There was no apparent correlation with any of the clinical parameters.

Capillary-like Formation in Three-dimensional Cultures of Cell Lines and Primary Melanoma Cell Cultures

It was suggested before that melanoma cells capable of forming VM structures are characterized by an endothelial phenotype, which enables them to form tubular networks when grown in 3D culture in vitro [8]. Indeed, tube formation activity was previously demonstrated with endothelial HUVEC cells and the highly aggressive (HAG) C8161 melanoma cell line, which is the commonly studied human cutaneous melanoma model for vasculogenic mimicry [8,22,40,41]. In contrast, the poorly aggressive (PAG) C816-61 melanoma cell line and normal human epidermal melanocytes (NHEM) did not form any tubes or networks (Figure 2A). Low-passage primary melanoma cultures (Table 1), derived from metastatic melanoma patients (Table S1) were tested for tube formation in matrigel. Several cultures exhibited a tube formation activity, while other cultures failed (Table 1, exemplar cultures shown in Figure 2B). There was no evidence for correlation between the VM capacity in situ and tube formation activity in vitro (p = 0.638).

VEGF-A is a known driver for tumor vasculogenesis [42], but a recent report suggested it has a role in VM as well [43]. Intracellular staining for VEGF-A content in HAG, PAG, HUVEC, NHEM and low-passage primary cultures Mel010 and Mel001 demonstrated its presence in all tested cells (Figure 2C). All cell cultures similarly expressed VEGF-A (MFI ranged from 10 to 35), except for HUVEC cells, which expressed a higher content of VEGF-A (MFI = 51) (Figure 2B). Therefore, the differential VM activity of melanoma cells cannot be entirely explained by different expression levels of VEGF-A (Figure 2C).

Based on the HAG and PAG model, it was previously reported that tube formation activity of tumor cells is associated with expression of VE-cadherin [44]. Indeed, almost all HAG cells expressed VE-cadherin, while essentially none of the PAG cells were VE-cadherin positive (Figure 2C and Table 1). In most of the primary melanoma cultures some VE-cadherin positive cells were identified (Figure 2D), but their frequency did not correlate to in vitro tube formation levels (p = 0.867) (Table 1). In addition, VE-cadherin expression in vitro did not correlate with VM capacity in situ (p = 0.998). In established cell lines on the other hand, VE-cadherin expression directly correlated with the ability to form VM channels on 3D matigel (Table 1).

Nicotinamide Induces a Robust Alteration in Gene Expression Profile Related to Vasculogenic Mimicry

Nicotinamide (NA) acts as an epigenetic gene regulator with a de-differentiating function on differentiated cells. HAG cells...
treated with 20 mM of NA for 3 days were subjected to whole genome expression microarray and compared with untreated control cells. A substantial number (1122) of significantly altered genes (>2-fold or <0.5-fold) was found. Remarkably, four of the nine most prominent gene clusters affected seem to have a close relation to vasculogenic mimicry: vasculature development, angiogenesis, cell migration and cell motility (Figure 3). More specifically, VE-cadherin (CDH5) was downregulated by 6.67 fold compared to control, as well as other key molecules such as VEGF-A, MMP2, TGF-β1 and SIRT5 (Table S2). These results strongly imply that NA has the potential to exogenously affect VM activity of melanoma cells in a consistent manner.

NA Abrogates VM Activity of Melanoma Cells

The effect of NA on VM activity was tested in two main setups: destruction of existing VM structures and prevention of tube formation. In the first experiments, HAG cells were seeded on matrigel and cultured for 24 h to allow development of VM structures. Then, NA was added onto the 3D culture in a final concentration of 5 mM and 20 mM. Vehicle-only served as negative control. A prominent dose-dependent destruction of preformed VM structures was observed (Figure 4A). In the second setup, HAG cells were cultivated for one month in the presence of 5 mM or 20 mM of NA, or vehicle-only, and tested for VM activity (without NA in the assay). Again, a prominent dose-dependent inhibition of VM activity was evident (Figure 4B). Finally, we tested the durability of the VM inhibitory effect by NA.

HAG cells were exposed to the same NA concentrations as above for 72 hours, washed and further cultivated in NA-free medium. Strikingly, the inhibitory effect on VM formation was maintained in a dose-dependent manner even one month after NA withdrawal (Figure 4C). Viability was equally high in all cell cultures. Quantification of total tube length was performed using ImageJ. The qualitative assessment of micrographic captures (Figure 4 A–C) concurred with the quantitative total length analysis (Figure 4D). In agreement with the downregulation of VE-cadherin in the microarray and the VM inhibitory effects of NA, a dose-dependent downregulation of VE-cadherin was observed at the protein level (Figure 4E). In contrast, VEGF expression was not affected by NA treatment (Figure 4F).

It can be concluded that downregulation of VE-cadherin by NA at least partially explains the inability of melanoma cells to form vasculogenic-like networks in the presence of NA.

Effect of NA on Proliferation, Invasion and Cell Cycle Profile of Melanoma Cells

The effect of NA on the phenotype of melanoma cells, including proliferation, cell cycle profile and invasion, was tested. As shown in Figure 5A, a pronounced and statistically significant inhibition of net proliferation of HAG melanoma cells treated with NA was evident in a dose-dependent manner, as compared to untreated cells. These observations were confirmed by cell cycle profiling, which revealed moderate changes in apoptotic indices and percentage of cells in the S+G2M phase in NA-treated cells.
Nicotinamide Inhibits VM

Table 1. Vasculogenic mimicry characteristics.

| Primary melanoma | PAS positive (%) paraffin section* | Tube formation (Matrigel) | VE-Cadherin (%)** |
|------------------|-----------------------------------|--------------------------|-------------------|
| 001              | 91                                | –                        | 14.0 ± 3.0        |
| 003              | 37                                | ++                       | 38.0 ± 7.0        |
| 005              | 44                                | ++                       | 44.0 ± 7.0        |
| 008              | 29                                | ++                       | 48.0 ± 1.0        |
| 010              | 78                                | +++                      | 43.0 ± 3.0        |
| 04               | 29                                | –                        | 19.0 ± 5.0        |
| 05               | 51                                | ++                       | 27.0 ± 3.0        |
| 06               | 41                                | –                        | 58.0 ± 9.0        |
| 08               | 33                                | +                        | 15.0 ± 0.0        |
| 09               | 25                                | ++                       | 19.0 ± 6.0        |
| 10               | 13                                | +                        | 50.0 ± 24         |
| 12               | 5                                 | +++                      | 17.0 ± 0.0        |
| 13               | 65                                | +++                      | 38.0 ± 7.0        |
| 14               | 26                                | +++                      | 28.0 ± 12         |
| 15               | 53                                | +                        | 31.0 ± 4.0        |
| Established cell lines |                          |                          |                  |
| HAG              | nd                                | +++                      | 80.0 ± 2.7        |
| PAG              | nd                                | –                        | 0.4 ± 0.2         |
| Primary cultures |                                  |                          |                  |
| HUVEC            | nd                                | +++                      | 75.0 ± 9.0        |
| NHEM             | nd                                | –                        | 0.3 ± 0.05        |

nd = not determined.

*CD31-PAS double-staining calculate as NVM structures (NVM structures + NCD31-positive structures) × 100.

**Percentage of VE-cadherin expression was determined by FACS analysis. doi:10.1371/journal.pone.0057160.t001

(Figure 5C and D). Interestingly, NA treatment enhanced the invasion activity of HAG cells, again in a dose-dependent manner (Figure 5B).

Discussion

VM formed by highly aggressive melanoma cells is a novel form of tumor microcirculation pattern, which differs from classically described endothelium-dependent angiogenesis. Previous studies demonstrated the prognostic value of VM in primary melanomas, using metastatic recurrence as an endpoint [8,13,14]. It should be emphasized that all of specimens in this study were already derived from metastases, and indeed VM was abundantly identified in almost all of the specimens (Figure 1, Table S1). There were no clinical associations with additional parameters such as age, gender, site of metastasis, size of tumor etc. It is therefore hypothesized that VM enables resistance to conventional anti-angiogenic medications. Taking into consideration that VM is an example of tumor cell plasticity displaying highly dedifferentiated phenotype, targeting this phenomenon is a complex task. It has been demonstrated that several drugs could inhibit VM [reviewed in [26]]. In this study, we found that NA could inhibit VM formation of the highly aggressive (HAG) melanoma cell line C8161 in vitro. NA also reduced proliferation and increased invasion capacity, as well as cause apoptosis to a certain degree. It is possible that these effects could contribute indirectly to the inhibition of VM. Notably, it was previously reported that VM is associated with invasion [28], which was increased here by NA, thus arguing against a significant indirect mechanism. In addition, VM was still inhibited even one month after washout of NA (Figure 4). Defining the molecular mechanisms underlying VM will further enable development of specific anti-VM strategies.

It was suggested that vascular channels in general, including VM channels, play a role not only in supplying oxygen and nutrients required for tumor growth, but also in enhancing tumor metastasis [7,45]. We found in a series of clinical metastatic melanoma specimens both CD31-positive endothelial channels and CD31-negative PAS-positive VM channels. Importantly, the proportion of VM was, on average, similar to that of endothelial blood vessels, supporting a significant role for VM. In addition, we observed the unique architectures that were described by Folberg et al [46] based on PAS staining, which are: straight channels, parallel straight pattern, parallel straight pattern with cross link, arcs (not closed), arcs with branching, closed loops, and networks.

Most of the literature data on VM in human cutaneous melanoma emerges from investigations on the model of C8161 (HAG) and C81-61 (PAG) isogenic, homogenous, cell lines. We were able to demonstrate tube formation activity of low-passage primary cultures of metastatic melanoma however it was not correlative to the percentage of VM channels observed in the paraffin embedded biopsies. It was previously reported that VM activity is associated with the expression of VE-cadherin, based on studies with HAG (VE-cadherin-High) and PAG (VE-cadherin - Negative) cells [44], jointly with the tyrosine kinase receptor EphA2, which was proposed as initiator of the VM signaling cascade [40,44,47]. An association between the expression of VE-cadherin and VM activity in vitro was mainly evident among established cell lines, and less among low-passage primary cultures (Table 1). The latter might be explained by the phenotypic heterogeneity and sensitivity to environmental manipulation of low-passage primary melanoma cultures [48]. While in vivo a small proportion of VE-cadherin positive cells might suffice for generation of capillary-like structures, the in vitro conditions are probably more restrictive. This might also explain why there was no correlation between VM in situ and tube formation activity in vitro. Therefore, mechanistic VM studies in vitro are limited to selected cell lines with an extreme phenotype, such as HAG, evident by the bright VE-cadherin expression. Nevertheless, targeting VM is still attractive. With the challenge of finding new drugs which could inhibit VM, the soybeans isoflavone Genistein [49] was found to be able to inhibit VM formation of uveal melanoma through down-regulation of VE-cadherin in vitro [50]. In the present study, we show that treatment with NA downregulates VE-cadherin expression to inhibit VM activity. It could be proposed that NA abrogate channel-like structures directly by downregulation the most essential molecule for VM network formation. Indeed, VE-cadherin was downregulated significantly in both RNA (Table S2) and protein (Figure 4E) levels, whereas VEGF-A was downregulated at the RNA level (Table S2), but not in the protein level (Figure 4F).

Hypoxia was found to encourage tube formation in vitro and expression of genes associated with VM [51]. Consequently, VM is mostly resistant to anti-angiogenic therapy [21,22], and is therefore probably involved metastasis through VM endorsement [52]. NA was found to act by decreasing perfusion-limited tumor hypoxia through prevention of intermittent vascular shut-down [36,53]. Another possible mechanism of action in vitro for NA could be inhibition of VM formation through prevention of local hypoxia. Indeed, the VE-cadherin gene contains genomic binding sites for HIF-1α and HIF-2α transcription factors that are stabilized during condition of hypoxia [54]. It was proposed that
HIF-2α expression in aggressive tumor cells is associated with dedifferentiation towards the endothelial lineage by transcriptional induction of VE-cadherin [25].

The ability of plastic tumor cells to present an endothelial phenotype is probably due to the reactivation of embryonic signaling cascades causing aggressive tumor cell to dedifferentiate [55]. In addition, melanoma cells appear to reversibly generate stem-like cells through “phenotype switching”. By this process, melanoma cells can switch between migratory, stem-like state and proliferative state in response to changes in microenvironmental conditions [56]. In the present study we observed that NA inhibited proliferation and enhanced invasiveness of HAG cells in vitro (Figure 5). It could imply that NA has a potential role in phenotype switching, but this must be thoroughly investigated in primary cultures in future studies (Figure 5). In a recent review, Girouard and Murphy [57] proposed that the undifferentiated, primitive, embryonic like stem cell profile of aggressive melanoma cells engage in VM, implying that melanoma stem cell may give rise to the patterned networks that characterize VM. Monzani et al [58] showed that a stem cell population that potentially increases tumor progression, is found in melanoma biopsies. Thus, it is suggested that cancer stem cell (CSC) subpopulation inside the tumor are capable of organizing VM networks, depending on the environmental condition. All of these contribute to the failure of current therapeutic regimens by masking malignant target populations.

It has been observed in a mouse model that invasive phenotype cells escape melanoma allograft in large numbers [59]. Hoek and Goding [56] suggested that cells with invasive phenotype possibly submitted to senescence or apoptosis and only a fraction survive to switch back to the proliferative state. Alternatively, they proposed that the switch from invasive to proliferative is very low, which may lead to dormancy over long periods. The complexity of the metastatic phenotype, including heterogeneity and phenotype-switching, with plasticity close to that of embryonic cells, must be taken into account when designing new therapies. NA addresses

Figure 2. Tube formation activity in vitro by low-passage primary melanoma cultures. (A) Vessel-like networks in three-dimensional culture of cell lines: C8161 (HAG) and HUVEC (positive controls) and C81-61 (PAG) and NHEM (negative controls). Original magnification as indicated in images; (B) Vessel-like networks in three-dimensional culture of primary low-passage melanoma cultures: Mel-010 and Mel-14 (positive) and Mel-04 and Mel-001 (negative); (C) intracellular VEGF-A expression by indicated cells. Shaded histograms denote isotype control antibody only and empty histograms denote VEGF-A staining; (D) percentage of VE-cadherin positive cells as determined by flow cytometry. The data represents one of three experiments with equal results.

doi:10.1371/journal.pone.0057160.g002
the need for designing such strategies combined with other modalities, including the molecular based approach aimed to suppress the aggressive melanoma phenotype in individual patients [60]. It was shown that NA had an effect of the differentiation of leukemia cells through its histone deacetylase inhibitory activity [61]. Recent studies in experimental human tumors showed antiproliferative proapoptotic activities by NA [62] and pronounced inhibition of growth and progression [63]. It is highly likely that the broad alterations in gene expression we observed in melanoma following exposure to NA and the subsequent functional effects are due to the epigenetic regulation exerted by NA, e.g. by histone deacetylase inhibition. Thus, NA could be viewed as a VM-targeted strategy in addition to its wide range of biological activities and its different effects mediated by different concentrations. The combination of anti-VM agents like NA with other therapeutic strategies is expected to yield the best results.

In conclusion, this study shows that NA could successfully inhibit the VM formation of C8161 human cutaneous melanoma. One mechanism in which NA inhibits VM is associated with downregulation of VE-cadherin. Moreover, NA inhibits proliferation and increases invasiveness and apoptosis in melanoma cells. This study may provide preliminary evidence for future and wider research to elucidate the mechanisms underlying VM inhibition by NA and its mode of action.

Materials and Methods

Patients

Melanoma lesions were surgically removed from 15 patients participating in a clinical study at the Ella Institute, Sheba Medical Center following approval of the local ethics committee of Sheba Medical Center, Tel Hashomer, Israel (Israeli Ministry of Health approval No. 3518/2004). All patients signed an informed consent form. Clinical characteristics of the melanoma patients are described in Table S1.

Cells

Primary melanoma cultures were established from the surgically removed melanoma lesions as previously described [64,65]. The tumor cultures were grown in RPMI (Lonza, Verviers Sprl, Belgium) containing 10% fetal bovine serum (FBS) (Gibco Minneapolis MN, USA), 25 mmol/l HEPES pH 7.2 (Lonza), 100 U/ml penicillin (Lonza), 100 mg/ml streptomycin (Lonza) and 1 mM sodium pyruvate (Lonza). Normal human epidermal melanocyte (NHEM) and human umbilical vein endothelial cells (HUVEC) was purchased from Promo Cell (Heidelberg, Germany). The cells were plated in endothelial growth medium or melanocyte growth medium, respectively, supplemented with growth factor mixture (Prom Cell) according to the manufacturer’s recommendation. The human cutaneous melanoma cell lines C8161 (highly aggressive-HAG) and C81-61 (poorly aggressive-PAG) were kindly provided by Dr. Marry Hendrix (Children’s Memorial research Center, Chicago, IL, USA) [66]. HAG cells were grown in RPMI as described above, while PAG cells were plated in Ham’s F10 medium (Biological Industries, Bet Haemek, Israel) supplemented with 15% FBS, 100 U/ml penicillin, 100 mg/ml streptomycin and 1 × MITO+ (BD Biosciences, Bedford, MA, USA).

Immunohistochemical and Periodic Acid-Schiff (PAS)

Histochemical Double-staining

Formalin-fixed, paraffin-embedded tissue samples derived from melanoma patients, parallel with the primary melanoma establishment, were available at the archives of the Department of Pathology of Sheba Medical Center. Tumor tissue sections of 4 μm were prepared, warmed up to 60°C for 1 h and deparaffinized in xylene and rehydrated. Antigen retrieval was performed using a microwave at 98°C for 16 min in 0.1 M citrate buffer pH 6. After 10 min cooling period, the slides were rinsed in TBS buffer and an endogenous peroxidase block was performed for 10 min in 3% H2O2/MeOH. After rinses in TBS, sections were blocked with 10% goat serum for 30 min at room temperature, and incubated overnight at 4°C with the primary antibody to human CD31 (Dako, Glostrup, Denmark). Detection was performed with the Histostain-SP-Broad-Spectrum kit (Invitrogen, Grand Island, NY, USA). The antibody binding was visualized with the substrate-chromogen AEC. Then, the sections were washed with running water for 3 min and incubated with PAS (American MasterTech, CA, USA) for 15 min. All sections were counterstained with hematoxylin and cover-slipped with an aqueous mounting fluid (glycergel).
VM and Endothelium-dependent Vessel Quantification

The CD31-PAS double-stained sections were viewed with a light microscope at a magnification of \( \times 400 \) and analyzed independently by two expert pathologists. Suitable digital images were captured using brightfield digital slide scanner (3DHISTECH Ltd, Budapest, Hungary) with Panoramic Viewer software. Vessels/linear spaces stained by CD31 were defined as endothelium-dependent vessels. Channels enclosed by melanoma cells (the absence of endothelial cells confirmed by hematoxylin-eosin staining), lined by PAS-positive material and negative for CD31 immunostaining were defined as VM. The average number of VM channels and endothelium-dependent vessels in each slide was determined in areas without necrosis in 10 randomly selected fields in each slide. The proportion of VM structures out of all vessels in each of the specimens was calculated as \( \frac{\text{NVVM structures}}{\text{NVVM structures} + \text{NCD31-positive structures}} \).

Assessment of Vasculogenic Network Formation in vitro (3D Matrix) and Image Analysis

The ability of melanoma cell lines and primary cultures to form vascular channels was assessed in vitro in three-dimensional collagen cultures on basemat membrane Matrix. Matrigel (45 \( \mu \)l BD Biosciences, Belgium) thawed on ice was dropped onto 96-well tissue culture plate and was allowed to polymerize for 45 min in a cell culture incubator [8]. \( 2 \times 10^4 \) tumor cells were then seeded on top of the solidified matrigel. Tube formation ability was evaluated after several hours to 24 hours and quantified by an image analysis process using whole field image capture (640 microscopic images) to avoid any bias. In principle, we quantified the distribution of the network lengths. First, a threshold was manually set to specifically demonstrate the network structures in the image. The quality and resolution of the images allowed reliable and exclusive threshold of the networks without the need of image filtering. Images were then placed in bins and subjected to the “Skeletonizer” function of ImageJ software. The corresponding lengths were measured using the 2D/3D skeleton PlugIn [67] for the NIH ImageJ software [60].

Periodic Acid-Schiff (PAS) Stain on Type I Collagen (3D Matrix)

The identification of patterned matrix type vasculogenic mimicry was performed by using type I collagen (R&D, Minneapolis, USA) following by PAS stain. 35 \( \mu \)l of type I collagen was dropped on 18 mm glass cover slips inserted to 12-well tissue culture plates. The collagen was allowed to polymerize for 1 hour at 37°C. \( 5 \times 10^4 \) cells were seeded on top of the collagen gel with overall culture medium volume of 2 ml. After seven day of cultivation a fixation was done with ethanol-formaldehyde solution for 15 min accompanied by washing with tap water for 1 min. PAS staining was carried out according to the manufacturer instruction using the material provide in the kit (Sigma-Aldrich, Israel).

Net Cell Proliferation

Melanoma cell net proliferation was determined by standardizedXTT colorimetric assay (Biological-Industries), as previously described [69]. Briefly, \( 3 \times 10^6 \) melanoma cells were seeded in triplicate wells in 96-well microplates. After background subtraction, the O.D. values were transformed into viable cells counts according to the specific regression equation that was determined for each cell group examined.

Invasion Assay

The invasive potential was quantified using matrigel-coated transwell system, as previously described [69]. Briefly, melanoma cells were harvested and re-suspended to concentration of \( 2 \times 10^7 \) ml in RPMI 1640 supplemented with 0.1% FBS. The cells (2 \( \times 10^7/100 \) ml) were then seeded into the upper wells of Transwell invasion system on Matrigel (BD Biosciences) coated ThinCerts PET 8-µm membranes (Greiner-bio-one, Germany). The lower well contained the same medium with 10% FBS. After 24 hours of incubation in humidified 5% CO2 incubator, the upper well content, which contained non-invading cells, was removed using cotton swabs. The amount of cells that invaded through the membranes was measured by standardizedXTT staining (as above) and corrected for proliferation. Percent of invasion was calculated out of the number of cells seeded.

Flow Cytometry

The expression of VE-cadherin (CD144) and VEGF-A was analyzed by flow cytometry using mouse anti-human VE-cadherin: biotin conjugate (Clone 16B1, e-Bioscience, CA, USA), FITC conjugated rabbit anti-human CD144 (SeroTec, Oxford, UK) and APC-conjugated mouse anti-human VEGF monoclonal antibody (R&D Systems, Minneapolis, MM, USA) with APC mouse IgG2b isotype control (e-Bioscience). The cells were removed with Trypsin-EDTA solution (Lonza, Verviers Sprl, Belgium), washed and re-suspended with cold PBS containing 0.5% bovine serum albumin (BSA), 2 mM EDTA and 0.002% NaN3 (FACS buffer) to a concentration of \( 2 \times 10^6 \) cells/ml. Afterward, \( 2 \times 10^5 \) cells were incubated on ice with the appropriate antibodies for 30 min. For VEGF-A, an intracellular staining (fixation with 2% PFA and permeabilization with saponine buffer \(-0.1% \) saponine; 0.2% BSA; 0.002% NaN3) was performed after over-night incubation with monensin (e-Bioscience, CA, USA) an intracellular protein transport blocker. Once the cells were washed (500 g, 5 min) and re-suspended with 200 ml FACS buffer, the samples were analyzed with a FACS-Calibur (Becket Dickinson, San Jose, CA) with WinMDI 2.9 Joseph Trotter Scripps data processing or with FlowJo software. The secondary antibody that was used is: PE-conjugated streptavidin (e-Bioscience).
Figure 5. Effect of NA on proliferation, invasion and cell cycle profile of melanoma cells. (A) Net proliferation of HAG cells was quantified with standardized XTT test. The number of cells was determined 72 h after seeding. The number of the vehicle-treated control cells was determined.
Proliferation Capacity and Apoptotic Cell Content

Cell cycle phase distribution according to DNA content analysis was performed using flow cytometry, by incubation of cells with propidium iodide (50 μg/ml) following the procedure of Vindelov [70]. This assay enabled to quantify the proliferative cell fraction (S+G2M) as well as the apoptotic fraction (Sub G1). The data was analyzed on FlowJO Software.

Gene Expression Microarray Analyses

Whole genome expression oligonucleotide microarray analyses were carried out on HAG melanoma cell line treated with 20 mM nicotinamide (Sigma Aldrich) compared to vehicle-treated cells. Total RNA was extracted and processed using TRIZol® Reagent (Ambion, TX, USA), including phase separation by chloroform, RNA precipitation with isopropanol alcohol and RNA washing with 75% ethanol. The quality and integrity of the RNA were confirmed by agarose gel electrophoresis and ethidium bromide staining, followed by visual examination under ultraviolet light. Total RNA was used as template to generate cDNA with a High-capacity reverse transcriptase kit (Applied Biosystems) using random hexamer primers. Subsequent biotinylated target cRNA was processed by an Affymetrix GeneChip Instrument System (Affymetrix) according to manufacturer’s recommendations. The differential expressed genes were analyzed by Ingenuity Pathway Analysis (http://www.ingenuity.com) and Topgene algorithm [71]. Full microarray data are deposit in NCBI GEO archive.

Statistical Evaluation

Statistical evaluation was performed for most data by Student’s t test. The Likelihood ratio significance test for ordinary logistic regression was used for examines correlations between VM in situ (PAS positive) and VM formation in vitro (tube formation) and between the last and VE-cadherin expression of primary cultured melanoma cells.

Supporting Information

Table S1 Patients clinical characteristics. (DOC)

Table S2 Comparative whole genome expression microarray. HAG cell line treated with 20 mM NA compared to vehicle-treated cells. (XLS)

Acknowledgments

The authors would like to thank Dr. Monika Huszar for assisting in data interpretation, to Daniel Ohayon for statistical analysis and to Haya and Nehemia Lennelbaum for their support.

This work was performed in partial fulfillment of the requirements for a Ph.D. degree of Eyal Greenberg, Sackler Faculty of medicine, Tel Aviv University, Israel.

Author Contributions

Conceived and designed the experiments: OI MJB GM. Performed the experiments: OI EG. Analyzed the data: OI EG BS AK AJT RSF RO. Wrote the paper: OI MJB JS GM.

References

1. Glover HM, Jr., Brodland DG (1996) The epidemiology of skin cancer. Dermatol Surg 22: 217–226.
2. Houghton AN, Polyk D (2002) Focus on melanoma. Cancer Cell 2: 275–278.
3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507–2516.
4. Rosenberg SA (2011) Cell transfer immunotherapy for metastatic solid cancer: what clinicians need to know. Nat Rev Clin Oncol 8: 377–385.
5. Kirkwood JM, Turbini AA, Panelli MC, Moschos SJ, Zareef HM, et al. (2008) Next generation of immunotherapy for melanoma. J Clin Oncol 26: 3445–3455.
6. Bittner M, Meltzer P, Chen Y, Jiang Y, Sefor E, et al. (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406: 536–540.
7. Hendrix MJ, Sefor EA, Hess AR, Sefor RE (2003) Molecular plasticity of human melanoma cells. Oncogene 22: 3070–3075.
8. Maniotis AJ, Folberg R, Hess A, Sefor EA, Gardner LM, et al. (1999) Vascular channel formation by human melanoma cells in vivo and in vitro: vasogenic mimicry. Am J Pathol 155: 739–752.
9. Hendrix MJ, Sefor EA, Hess AR, Sefor RE (2003) Vasogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 3: 411–421.
10. Zhang S, Zhang D, Sun B (2007) Vasogenic mimicry: current status and future prospects. Cancer Let 254: 157–164.
11. Sefor RE, Sefor EA, Koshikawa N, Meltzer PS, Gardner LM, et al. (2001) Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasogenicesis by aggressive melanoma. Cancer Res 61: 6322–6327.
12. Folberg R, Maniotis AJ (2004) Vasogenic mimicry. APMIS 112: 501–525.
13. Thies A, Mangold U, Moll I, Schumacher U (2001) PAS-positive loops and networks as a prognostic indicator in cutaneous malignant melanoma. J Pathol 195: 537–542.
14. Waco MA, Maniotis AJ, Chen X, Majumdar D, Patel MK, et al. (2001) Prognostic significance of periodic acid-Schiff-positive patterns in primary cutaneous melanoma. Clin Cancer Res 7: 473–477.
15. Vartanian AA, Stepanova EV, Gurtov M, Solomeno E, Grigorieva IN, et al. (2009) Prognostic significance of periodic acid-Schiff-positive patterns in clear cell renal cell carcinoma. Can J Urol 16: 4726–4732.
16. Shirakawa K, Wakasugi H, Heike Y, Watanabe I, Yamada S, et al. (2002) Vasogenic mimicry and pseudo-corded formation in breast cancer. Jnt J Cancer 99: 821–829.
17. Sood AK, Fletcher MS, Zahn CM, Gruman LM, Coffin JE, et al. (2002) The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vascugenesis therapy. Cancer Biol Ther 1: 661–664.
18. Sun B, Zhang S, Zhang D, Du J, Guo H, et al. (2006) Vasogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol Rep 16: 693–698.
19. Guzman G, Cotler SJ, Lin AY, Maniotis AJ, Folberg R (2007) A pilot study of vasogenic mimicry immunohistochemical expression in hepatocellular carcinoma. Arch Pathol Lab Med 131: 1776–1781.
20. Emmert MS, Dewing D, Pritchard-Jones RO (2011) Angiogenesis and melanoma - from basic science to clinical trials. Am J Cancer Res 1: 852–868.
21. Rybak SM, Sanojich E, Hollingshead MG, Borgel SD, Newton DL, et al. (2003) “Vasocrine” formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies. Cancer Res 63: 2812–2819.
22. van der Schaft DW, Sefor RE, Sefor EA, Hess AR, Gruman LM, et al. (2004) Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Nat Cancer Inst 96: 1473–1477.
23. Hendrix MJ, Sefor EA, Sefor RE, Kasemierz-Kulesa J, Kulesa PM, et al. (2007) Reprogramming metastatic tumour cells with embryonic microenvironments. Nat Rev Cancer 7: 246–255.
24. Hess AR, Margaryan NV, Sefor EA, Hendrix MJ (2007) Deciphering the signaling events that promote melanoma tumor cell vasogenic mimicry and...
Nicotinamide Inhibits VM

their link to embryonic vasculogenesis: role of the Eph receptors. Dev Dyn 236: 3283–3296.
25. Paulis YW, Soretoukou PM, Verheul HM, Tjan-Heijnen VC, Grifffen AW (2010) Guiding pathways in vasculogenic mimicry. Biochim Biophys Acta 1806: 10–28.
26. Fan YZ, Sun W (2010) Molecular regulation of vasocogenic mimicry in tumors and potential tumor-target therapy. World J Gastrointest Surg 2: 117–127.
27. Hardy KM, Kirschmann DA, Seftor EA, Margaryan NV, Postovit LM, et al. (2010) Regulation of the embryonic morphogen Nodal by Notch facilitates manifestation of the aggressive melanoma phenotype. Cancer Res 70: 10340–10350.
28. Seftor EA, Melzner PS, Kirschmann DA, Margaryan NV, Seftor RE, et al. (2006) The epigenetic reprogramming of poorly aggressive melanoma cells by a metastatic microenvironment. J Cell Mol Med 10: 174–196.
29. Maise K, Chong ZZ, Hou J, Shang YC (2009) The vitamin nicotinamide: translating nutrition into clinical care. Molecules 14: 3446–3465.
30. Namazi MK (2003) Nicotinamide: a potential addition to the anti-psoriatic weaponry. FASEB J 17: 1377–1379.
31. Surjana D, Halliday GM, Damian NV (2010) Role of nicotinamide in DNA damage, mutagenesis, and DNA repair. J NuclAcids 2010.
32. Yi J, Luo J (2010) SIRT1 and p53, effect on cancer, senescence and beyond. Biochim Biophys Acta 1804: 1684–1689.
33. Gender HL, Williams T, Huang AC, Jacobson EL (1999) Oral niacin prevents photocarcinogenesis and photoimmunosuppression in mice. Nutr Cancer 34: 36–41.
34. Yi J, Luo J (2010) SIRT1 and p53, effect on cancer, senescence and beyond. Biochim Biophys Acta 1804: 1684–1689.
35. Jacobson EL, Jacobson MK (1993) A biomarker for the assessment of niacin nutrition as a potential preventive factor in carcinogenesis. J Intern Med 233: 59–62.
36. Horsman MR, Chaplin DJ, Brown JM (1989) Tumor radiosensitization by concurrent carbon and nicotinamide in bladder carcinoma. J Clin Oncol 28: 4912–4918.
37. Vaca P, Bena G, Martin F, Soria B (2003) Nicotinamide induces both phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res 61: 101–105.
38. Jacobson EL, Jacobson MK (1993) A biomarker for the assessment of niacin nutrition as a potential preventive factor in carcinogenesis. J Intern Med 233: 59–62.
39. Maiese K, Chong ZZ, Hou J, Shang YC (2009) The vitamin nicotinamide: translating nutrition into clinical care. Molecules 14: 3446–3465.
40. Yiasemides E, Sivapirabu G, Halliday GM, Park J, Damian NV (2009) Oral nicotinamide increases the phosphorylation of E-cadherin: role of the Eph receptors. Dev Dyn 236: 728–737.
41. Orgaz JL, Ladhani O, Hoek KS, Fernandez-Barral A, Mihic D, et al. (2009) Vasculogenic mimicry and tumor angiogenesis. Pigment Cell Melanoma Res 23: 746–759.
42. Horsman MR, Chaplin DJ, Brown JM (1989) Tumor radiosensitization by concurrent carbon and nicotinamide in bladder carcinoma. J Clin Oncol 28: 4912–4918.
43. Welch DR, Bisi JE, Miller BE, Conaway D, Seftor EA, et al. (1991) Expression and functional significance of VE-cadherin in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol Ther 5: 2280–2283.
44. Orzu JL, Labadany O, Hook KS, Fernandez-Barral A, Mihic D, et al. (2009) ‘Loss of pigment epithelium-derived factor enables migration, invasion and metastatic spread of human melanoma’. Oncogene 28: 1139–1150.
45. Vindelov LL, Christensen IJ, Nissen NI (1983) Standardization of high-resolution flow cytometric DNA analysis by the simultaneous use of chicken and mouse cell lines. Microsc Res Tech 28: 711–717.
46. Fan YZ, Sun W (2010) Molecular regulation of vasocogenic mimicry in tumors and potential tumor-target therapy. World J Gastrointest Surg 2: 117–127.
47. Hardy KM, Kirschmann DA, Seftor EA, Margaryan NV, Postovit LM, et al. (2010) Regulation of the embryonic morphogen Nodal by Notch facilitates manifestation of the aggressive melanoma phenotype. Cancer Res 70: 10340–10350.
48. Seftor EA, Melzner PS, Kirschmann DA, Margaryan NV, Seftor RE, et al. (2006) The epigenetic reprogramming of poorly aggressive melanoma cells by a metastatic microenvironment. J Cell Mol Med 10: 174–196.
49. Maise K, Chong ZZ, Hou J, Shang YC (2009) The vitamin nicotinamide: translating nutrition into clinical care. Molecules 14: 3446–3465.
50. Namazi MK (2003) Nicotinamide: a potential addition to the anti-psoriatic weaponry. FASEB J 17: 1377–1379.
51. Surjana D, Halliday GM, Damian NV (2010) Role of nicotinamide in DNA damage, mutagenesis, and DNA repair. J NuclAcids 2010.
52. Yi J, Luo J (2010) SIRT1 and p53, effect on cancer, senescence and beyond. Biochim Biophys Acta 1804: 1684–1689.
53. Gender HL, Williams T, Huang AC, Jacobson EL (1999) Oral niacin prevents photocarcinogenesis and photoimmunosuppression in mice. Nutr Cancer 34: 36–41.
54. Yi J, Luo J (2010) SIRT1 and p53, effect on cancer, senescence and beyond. Biochim Biophys Acta 1804: 1684–1689.
55. Jacobson EL, Jacobson MK (1993) A biomarker for the assessment of niacin nutrition as a potential preventive factor in carcinogenesis. J Intern Med 233: 59–62.
56. Horsman MR, Chaplin DJ, Brown JM (1989) Tumor radiosensitization by concurrent carbon and nicotinamide in bladder carcinoma. J Clin Oncol 28: 4912–4918.
57. Vaca P, Bena G, Martin F, Soria B (2003) Nicotinamide induces both phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res 61: 101–105.
58. Jacobson EL, Jacobson MK (1993) A biomarker for the assessment of niacin nutrition as a potential preventive factor in carcinogenesis. J Intern Med 233: 59–62.
59. Maiese K, Chong ZZ, Hou J, Shang YC (2009) The vitamin nicotinamide: translating nutrition into clinical care. Molecules 14: 3446–3465.
60. Yiasemides E, Sivapirabu G, Halliday GM, Park J, Damian NV (2009) Oral nicotinamide increases the phosphorylation of E-cadherin: role of the Eph receptors. Dev Dyn 236: 728–737.
61. Orgaz JL, Ladhani O, Hoek KS, Fernandez-Barral A, Mihic D, et al. (2009) ‘Loss of pigment epithelium-derived factor enables migration, invasion and metastatic spread of human melanoma’. Oncogene 28: 1139–1150.
62. Vindelov LL, Christensen IJ, Nissen NI (1983) Standardization of high-resolution flow cytometric DNA analysis by the simultaneous use of chicken and mouse cell lines. Microsc Res Tech 28: 711–717.
63. Fan YZ, Sun W (2010) Molecular regulation of vasocogenic mimicry in tumors and potential tumor-target therapy. World J Gastrointest Surg 2: 117–127.
64. Hardy KM, Kirschmann DA, Seftor EA, Margaryan NV, Postovit LM, et al. (2010) Regulation of the embryonic morphogen Nodal by Notch facilitates manifestation of the aggressive melanoma phenotype. Cancer Res 70: 10340–10350.
65. Seftor EA, Melzner PS, Kirschmann DA, Margaryan NV, Seftor RE, et al. (2006) The epigenetic reprogramming of poorly aggressive melanoma cells by a metastatic microenvironment. J Cell Mol Med 10: 174–196.